Spinal Cord Stimulation as a Treatment Option for Refractory Chemotherapy-Induced Peripheral Neuropathy: Case Report

Lopes, António; Duarte, Kléber Paiva; Lins, Catarina Couras; Kubota, Gabriel Taricani; Silva, Valquíria; Galhardoni, Ricardo; Menezes, Luciana Mendes Bahia; Raicher, Irina; Teixeira, Manoel Jacobsen; Andrade, Daniel Ciampi de

doi:10.1055/s-0040-1709985

Cited by 5 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, the studies comprised 73 total participants. Of these, 15 studies [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ] utilized SCS ( n = 16 participants), 7 studies [ 43 , 44 , 45 , 46 , 47 , 48 , 49 ] utilized DRG-S ( n = 7 participants), and 1 study [ 27 ] utilized PNS ( n = 50 participants).…”

Section: Resultsmentioning

confidence: 99%

“…SCS therapy for CIPN-related pain was evaluated across 15 case studies [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ] and reported in Table 1 . A total of 3 recent case reports reported improvement in pain intensity by 80% during the trial phase, which was maintained after permanent SCS implantation, with visual analog scale (VAS) scores ranging between 0/10 and 2/10 at 2 years follow-up [ 28 , 35 , 36 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition in patients who have received chemotherapy. The role of neuromodulation therapy in treating pain and improving neurological function in CIPN remains unclear and warrants evidence appraisal. In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review to assess change in pain intensity and neurological function after implementation of any neuromodulation intervention for CIPN. Neuromodulation interventions consisted of dorsal column spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), or peripheral nerve stimulation (PNS). In total, 15 studies utilized SCS (16 participants), 7 studies utilized DRG-S (7 participants), and 1 study utilized PNS (50 participants). Per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria, there was very low-quality GRADE evidence supporting that dorsal column SCS, DRG-S, and PNS are associated with a reduction in pain severity from CIPN. Results on changes in neurological function remained equivocal due to mixed study findings on thermal sensory thresholds and touch sensation or discrimination. Future prospective, well-powered, and comparative studies assessing neuromodulation for CIPN are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For painful diabetic peripheral neuropathy, a phenotypically comparable condition, significant reductions in pain scores and improvements in quality of life have been demonstrated with SCS [31]. In contrast, the evidence for SCS in CIPN is limited to case reports and pain behaviour changes in animal models [32][33][34]. The case reports include neuropathy caused by a number of different agents, which, whilst of interest do not yet provide a particularly robust justification for its use in this condition.…”

Section: Spinal Cord Stimulationmentioning

confidence: 99%

Neuromodulation techniques for cancer pain management

Magee

Schutzer-Weissmann

Pereira

et al. 2021

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewAdvanced pain management techniques may be indicated in 5-15% of cancer patients. Despite this, a recent review identified that, over the course of 1 year in England, only 458 patients received a procedure intended to provide analgesia and only 30 patients had intrathecal drug delivery (ITDD) devices implanted. This article describes the emerging evidence for ITDD in cancer pain and provides a narrative review of other neuromodulatory techniques (including spinal cord stimulation, peripheral nerve stimulation and acupuncture), approaches that might be employed to address this area of significant unmet clinical need. Recent findingsNumerous studies have been published within the last year reporting positive outcomes associated with ITDD in cancer pain management. Neuromodulation represents an important strategy in the management of persistent pain. Whilst the nonmalignant pain evidence-base is rapidly growing, it remains sparse for cancer pain management. The growing cohort of cancer survivors may significantly benefit from neuromodulatory techniques. SummaryITDD and other neuromodulatory techniques for cancer pain management appear underutilised in the UK and offer the prospect of better treatment for cancer patients with refractory pain or intolerable side-effects from systemic analgesics.

show abstract

Oxaliplatin

2020

Reactions Weekly

View full text Add to dashboard Cite

Spinal Cord Stimulation as a Treatment Option for Refractory Chemotherapy-Induced Peripheral Neuropathy: Case Report

Cited by 5 publications

References 14 publications

Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review

Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review

Neuromodulation techniques for cancer pain management

Oxaliplatin

Contact Info

Product

Resources

About